Paul Clancy

Track

Insider profile

Currently holds positions in Agios Pharmaceuticals Inc and Incyte Corp

Performance

Overall performance
Performance over holding periods
30 days 90 days 120 days
Average return -3% 8.2% 15.1%
Success rate 0% 68% 82%
Transactions
2 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Agios Pharmaceuticals Inc Sept. 24, 2013 -
Independent Director Incyte Corp Jan. 20, 2015 -
Chief Financial Officer, Executive Vice President Alexion Pharmaceuticals Inc July 31, 2017 - Sept. 17, 2019
Chief Financial Officer, Executive Vice President - Finance Biogen Inc Aug. 13, 2007 - June 30, 2017
Paul Clancy's trades of Incyte Corp's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
US Incyte Corp (INCY)
Transaction date
Sale
Price
119.41
Quantity 71,569 -44.2%
Value US$4,336,826
US Incyte Corp (INCY)
Transaction date
Sale
Price
364.80
Quantity 39,611 -16.5%
Value US$1,074,681
US Incyte Corp (INCY)
Transaction date
Proposed sale
Price
474.20
Quantity 83,326
Value US$1,175,812
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-21 2026-05-19
US Incyte Corp (INCY)
S Sale
71,569 -44.2%
119.41
US$4,336,826 		71,569 -44.2% 119.41 US$4,336,826
2026-05-21 2026-05-19
US Incyte Corp (INCY)
S Sale
39,611 -16.5%
364.80
US$1,074,681 		39,611 -16.5% 364.80 US$1,074,681
2026-05-19 2026-05-19
US Incyte Corp (INCY)
PrS Proposed sale
83,326
474.20
US$1,175,812 		83,326 474.20 US$1,175,812
2018-02-08 2018-02-08
S Sale
6,079 -6.4%
116.31
US$707,048 		6,079 -6.4% 116.31 US$707,048